CTi Biopharma Corp Financials
Based on the key measurements obtained from CTi Biopharma's financial statements, CTi Biopharma Corp is not in a good financial situation at the moment. It has a very high risk of going through financial straits in April.
CTi |
Understanding current and past CTi Biopharma Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of CTi Biopharma's financial statements are interrelated, with each one affecting the others. For example, an increase in CTi Biopharma's assets may result in an increase in income on the income statement.
Please note, the presentation of CTi Biopharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, CTi Biopharma's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of CTi Biopharma's management manipulating its earnings.
CTi Biopharma Stock Summary
CTi Biopharma competes with Rigel Pharmaceuticals, Fortress Biotech, Reviva Pharmaceuticals, Protalix Biotherapeutics, and Seres Therapeutics. CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington. Cti Biopharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 121 people.Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US12648L6011 |
Business Address | 3101 Western Avenue, |
Sector | Biotechnology |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.ctibiopharma.com |
Phone | 206 282 7100 |
Currency | USD - US Dollar |
CTi Biopharma Key Financial Ratios
Return On Equity | -10.19 | |||
Return On Asset | -0.29 | |||
Target Price | 10.05 | |||
Number Of Employees | 127 | |||
Beta | 0.83 |
CTi Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining CTi Biopharma's current stock value. Our valuation model uses many indicators to compare CTi Biopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across CTi Biopharma competition to find correlations between indicators driving CTi Biopharma's intrinsic value. More Info.CTi Biopharma Corp is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the CTi Biopharma's earnings, one of the primary drivers of an investment's value.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Other Consideration for investing in CTi Stock
If you are still planning to invest in CTi Biopharma Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the CTi Biopharma's history and understand the potential risks before investing.
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Equity Valuation Check real value of public entities based on technical and fundamental data |